- Home
- CRMD vs NXP Comparison
CRMD vs NXP Comparison
Compare CRMD & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- NXP
- Stock Information
- Founded
- CRMD 2006
- NXP 1992
- Country
- CRMD United States
- NXP United States
- Employees
- CRMD N/A
- NXP N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- CRMD Health Care
- NXP Finance
- Exchange
- CRMD Nasdaq
- NXP Nasdaq
- Market Cap
- CRMD 865.2M
- NXP 741.7M
- IPO Year
- CRMD 2010
- NXP N/A
- Fundamental
- Price
- CRMD $11.20
- NXP $14.41
- Analyst Decision
- CRMD Strong Buy
- NXP
- Analyst Count
- CRMD 8
- NXP 0
- Target Price
- CRMD $17.57
- NXP N/A
- AVG Volume (30 Days)
- CRMD 2.9M
- NXP 70.0K
- Earning Date
- CRMD 10-29-2025
- NXP 01-01-0001
- Dividend Yield
- CRMD N/A
- NXP 4.04%
- EPS Growth
- CRMD N/A
- NXP N/A
- EPS
- CRMD 0.79
- NXP 0.54
- Revenue
- CRMD $121,484,498.00
- NXP N/A
- Revenue This Year
- CRMD $446.49
- NXP N/A
- Revenue Next Year
- CRMD $59.96
- NXP N/A
- P/E Ratio
- CRMD $14.61
- NXP $26.81
- Revenue Growth
- CRMD 14970.29
- NXP N/A
- 52 Week Low
- CRMD $5.60
- NXP $12.91
- 52 Week High
- CRMD $17.43
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- CRMD 41.16
- NXP 56.39
- Support Level
- CRMD $10.95
- NXP $14.36
- Resistance Level
- CRMD $11.71
- NXP $14.55
- Average True Range (ATR)
- CRMD 0.53
- NXP 0.14
- MACD
- CRMD 0.01
- NXP -0.02
- Stochastic Oscillator
- CRMD 12.69
- NXP 21.67
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.